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including age, sex and time delays to admission. Interestingly, dyslipidemia and
history of MI was less frequent in PE group. Plasma CRP levels on admission
were markedly higher in PE patients. Prior chronic treatments were less frequent
in PE group, in particular for aspirin (11 vs 19%, p=0.027), ACE inhibitor (10 vs
18%, p=0.014) and statin (15 vs 23%, p=0.054). Acute treatments were similar,
except for BetaBlocker that were more used in patients without PE. Patients with
PE were more likely to suffer from STEMI and altered LVEF. Hospital complica-
tions such as death, or heart failure (12 vs 7%, p=0.016, 47 vs 28%, p=0.001), and
mechanical complications including atrial fibrillation, wall rupture, apical
thrombus and mitral regurgitation (respectively, 20 vs 9%, p<0.001, 7 vs 0.5%,
p<0.01, 8 vs 0.7%, p<0.01, and 8 vs 3%, p=0.03) were more frequent in PE group.
Conclusions: Our large study showed that, although PE is uncommon in
the contemporary era of acute MI, it is still associated with worse short term
prognosis, characterized by high rate of mechanical complications. Our works
also suggest a preventive effect of some CV drugs against the development of
PE following acute MI.
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fulness of a new definition
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Bellemain-Appaix, Farzin Beygui, Nicolas Vignolles, Guillaume Cayla,
Jean-Philippe Collet, Gilles Montalescot
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Objectives: The aim of this study was to assess the prevalence and impact
on outcome of CIN occurring after primary PCI (pPCI) for STEMI, in addi-
tion to the information provided by the measure of renal function.
METHODS: In 924 consecutive STEMI patients undergoing pPCI, we mea-
sured serum creatinine concentration (CrC) and calculated creatinine clearance
(CrCl) at admission (in the cath-lab) and each day during hospitalization.
Renal impairment was defined as a CrCl <60ml/min. CIN was defined #1 –
by an increase of 25% of Cr C between the baseline and the peak (classic def-
inition) and, # 2 – by a decrease of 25% of CrCl according to the Cockroft-
Gault Formula (new definition). 
Results: Renal impairment was found in 26.1% at admission and in 29.6% of
patients after the pPCI and had a major impact on in-hospital mortality (13.8% vs.
2.25% in patients without renal dysfunction, OR 7.1; p<0.0001). The relation was
even stronger after pPCI (15.6% vs. 1.7%, OR 8.8; p<0.0001). Using definition#1,
CIN occurred in 17.2% (159) of patients and was associated with a three-fold
increase in mortality when compared with patients without CIN (11.6% vs. 3.9%,
OR 3.2, p=0.0036). The rate of CIN was 11.3% (104) with definition #2 and asso-
ciated with a four-fold increase in mortality (15.3% vs. 4.0%, OR 4.3, p=0.0005).
The combined effect on in-hospital mortality of baseline renal impairment and
CIN after pPCI is shown on figure 1.The mean volume of contrast media was sim-
ilar in patients developing CIN or not (218±44 vs. 217±50; p=0.8 definition #1;
213±39 vs. 218±49; p =0.5 definition #2) and did not relate to survival either
(219± 9 ml vs. 216± 2 ml; p=0.7).
Conclusions: In STEMI patients CIN is a major factor of in-hospital death
when it occurs in patients with basal renal impairment and seem independent
to the amount of contrast media. A new definition of CIN based on CrCl
seems more sensitive to predict mortality.
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Introduction: The present study was designed to identify the mid and long
term impact of limitations of daily activities (functional decline) on outcome
in a cohort of elderly ACS patients.
Methods: Clinical data including the Global Registry of Acute Coronary
Events (GRACE) score and assessment of functional status using Katz scale
was prospectively collected in a cohort of 272 patients 70 years old admitted
for an ACS. All cause mortality was assessed at 6-month and in alive patients
after the initial 6 months of follow-up.
Results: Mean age was 78+/-6 years (men 58%). Functional decline was
diagnosed in 28% of the cohort. At 6-month follow-up 38 patients died and
during a median follow up of 611 [1-1320] days after 6-month post ACS,
29 patients died. Functional decline was associated with both 6-month and
long-term outcome (HR=3.629 [1.914-6.881], p<0.0001 and HR=2.69 (1.28-
5.64), p=0.009 respectively). Functional decline remained associated with
both 6 months and long-term outcome in multivariate analysis. Functional
decline was systematically selected in the most predictive multivariate models
for the prediction of 6-month and long-term mortality in term of global model
fit, calibration and discrimination. While the multivariate model including the
GRACE score and functional decline had a good predictive value for the pre-
diction of 6-months mortality, the combination of functional decline to biolog-
ical data (low estimated Glomerular Filtration Rate and haemoglobin) had a
better predictive value for the prediction of long-term mortality than a model
combining functional decline to the GRACE score.
Conclusions: The present study provides strong evidence that functional
decline represents a short – and long-term prognosticator in elderly ACS
patients. Functional decline should be considered to achieve coordinated care
and thereby improve outcome in elderly.
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Ismail Ghrissi, Wiem Selmi, Fatma Ben Amor, Zohra Dridi, Samer
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Background: Despite the superiority of primary angioplasty in the man-
agement of ST elevation myocardial infarction (STEMI), thrombolysis
remains more frequently used worldwide particularly in developing countries.
The aim of this analysis was to identify predictors of thrombolytic therapy
success in STEMI patients.
Methods: Among 1353 patients included in our MIRAMI (MonastIR
Acute Myocardial Infarction) registry between January 1995 and April 2011,
436 patients received thrombolysis. Streptokinase was the only lytic agent
used. Multivariate logistic regression was used to determine predictors of
thrombolysis success. 
Results: Thrombolysis success, defined as chest pain relief below 5 in a
scale from 1 to 10 and ST elevation resolution over 50% from baseline, was
obtained in 306 patients (70%). Time to treatment less than 3 hours (p=0.001;
OR= 2.13), smoking (p=0.001, OR=2.1), and inferior location (p=0.009,
OR=1.83) were identified as independent predictors of thrombolysis success.
Inversely, severe heart failure (Killip III and IV classes) were found to be pre-Mortality according to Renal Impairment and CIN
© Elsevier Masson SAS. All rights reserved.
 
Archives of Cardiovascular Diseases Supplements (2012) 4, 1-29 3
dictors of thrombolysis failure (p=0.006, OR=0.13 for class III, p=0.003,
OR=0.15 for class IV).
Conclusion: In our MIRAMI Registry, short time to treatment (< 3 hours),
smoking and inferior location of STEMI were predictors of thrombolysis suc-
cess , whereas severe heart failure was a predictor of its failure.
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assessment of a management therapy guided by IVUS imaging
Gilles Barone-Rochette [Orateur] (1), Estelle Vautrin (2), Stéphanie Mar-
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Background: Very late stent thrombosis (VLST) of Drug Eluting Stents
(DES) is a rare but severe complication whose physiopathology and manage-
ment remain unclear. 
Aim: We carried out a prospective systematic analysis DES mechanical
structure with intravascular ultrasound (IVUS) for all patients who presented
with VLST. After this analysis, we proposed a VLST management therapy. 
Methods: Between June 2009 and August 2010, we included consecu-
tively all cases of VLST (definite ST with any Academic Research Consor-
tium definition) in our university hospital. All patients underwent IVUS
imaging. A VLST management therapy was proposed with balloon angio-
plasty if malapposition or underexpansion were detected. One year follow up
was performed. 
Results: Ten cases (9 men, 1 woman; mean age 61 years [39-81]) were
identified. The index procedure indication was acute coronary syndrome in 8
patients and stable pectoris angina in 2 patients. The mean duration from
implantation to thrombosis was 52 ± 15 months (range 19 to 66 months). All
patients except one had a correct anti-agreggation therapy at the moment of
VLST. All patients analysed with IVUS imaging had evidence of stent under-
expansion and/or malapposition. During interventions IVUS findings led to
the use of higher pressures or larger balloons than those used during initial
stenting. After the procedure the final minimum stent area (10.5 vs. 7.9 mm²,
p=0.03) and % stent expansion improved compared with pre-interventional
values (86 vs. 66%, p=0.03). At the follow-up (15±4.5 months), all patients
are alive without new MACEs (cardiac death, non fatal infarction and ST). 
Conclusion: In VLST management, the selective use of IVUS after an ini-
tial mechanical reperfusion is an attractive option to optimise mechanical stent
features and appeared effective and safe at 1 year follow-up.
008
Unprotected left main stenting in the real world: five-year outcomes
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Background: Limited long-term outcome data is available to support the
use of drug-eluting stents in the treatment of unprotected left main (LM) cor-
onary artery disease.
Methods and Results: In this multicenter registry, 291 patients with
unprotected LM stenosis underwent percutaneous revascularization with pacl-
itaxel-eluting stents (Taxus Express), using a consistent technical approach for
both ostial/shaft and bifurcation lesions (provisional side-branch stenting). At
5 years, the cumulative incidence of major adverse cardiac events (MACE)
was 23.6%, and the crude rates of all-cause and cardiac death were 24.3% and
12.5% respectively. During follow-up, myocardial infarction occurred in
16 patients (6.1%) and the incidence of target lesion revascularization (TLR)
was 10.3%. Definite stent thrombosis occurred in 0.4%. There was no signif-
icant difference in outcomes between patients with ostial/shaft or bifurcation
lesions. In contrast, patients with distal LM lesions requiring two-stent proce-
dures had a higher rate of MACE than patients with single-stent interventions
(34.1% versus 17.8%, P=0.009). This was driven by an increased incidence of
cardiac death (18.2% versus 8.5%, P=0.05) and non-Q-wave MI (8.0% versus
1.7%, P=0.04) in the two-stent cohort. Patients with diabetes mellitus had an
increased rate of TLR compared to nondiabetic subjects (19.2% versus 6.8%,
P=0.005), and diabetes was an independent predictor of MACE at 5 years (OR
2.10, 95% CI 1.10-3.99, P=0.018).
Conclusions: These long-term results show that the treatment of unprotected
LM stenosis with paclitaxel-eluting stents is safe and efficacious. Outcomes
are similar for ostial/shaft and distal LM interventions, however single-stent
interventions should be the preferred strategy for distal LM lesions, as two-
stent techniques increase the risk of adverse events.
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large (≥3.0 mm) vessels in patients with diabetes mellitus?
Olivier Barthelemy [Orateur], G. Helft, Anne Bellemain-Appaix, J. Sil-
vain, F. Beygui, R. Choussat, Emmanuel Berman, Jean Philippe Collet, G.
Montalescot, Jean Philippe Metzger, Claude Le Feuvre
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Aim: To compare drug-eluting stent (DES) vs bare metal stent (BMS) in
diabetic patients treated by percutaneous coronary intervention (PCI) for short
lesions in large vessels (vessel diameter 3.0 mm AND length 15 mm). 
Methods: Consecutive patients treated with at least one large (3.0 mm)
and short (18 mm) stent were included over 29 months. Patients with MI,
cardiogenic shock or out-of-hospital cardiac arrest were excluded. We com-
pare the occurrence of 1) MACCE (cardiovascular (CV) death, myocardial
infarction and stroke), 2) Target Vessel (TVR) and – Lesion Revascularization
(TLR) and 3) definite Stent Thrombosis (ST) rates in the diabetic population
according to the type of stent used (DES vs BMS). 
Results: Six hundred eighty-six patients underwent PCI in large and short
lesions. Among the 189 (28%) patients with diabetes, 47% (n=89) had PCI
with BMS and 53% (n=100) with DES. Mean age was 66 ± 11 years, 34%
(n=64) had acute coronary syndrome. Patients treated with DES were younger
(64 vs. 69, p=0.001), had more prior PCI (41% vs. 22%, p=0.006) and more
multivessel disease (63% vs. 45%, p=0.013). Total stent length was higher in
the DES group (28±22 mm vs. 22±16 mm, p=0.043). One year follow-up was
completed for 100% of the patients. Twenty patients (10.5%) had MACCE, 17
(9.0%) TVR, 12 (6.3%) TLR and 3 (1.6%) ST. Figure shows event rates
according to the stent used. 
Conclusions: In diabetic patients treated by elective or emergent PCI of
short lesions in large vessels, comparable rates of TLR, TVR and Stent throm-
bosis were observed between DES and BMS. However, the DES group had a
higher risk profile of restenosis.
One year event rates
